Dibutyryl-cGMP sodium | 51116-00-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: Dibutyryl-cGMP sodium
• CAS: 51116-00-8
• 化学式: C18H24N5NaO9P
• 分子量: 508.4
• InChiKey: NYJYLSMMHGCJLV-GBIKJYCISA-N

物化性质

• 溶解度：
  H2O:50 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  180
• 氢给体数：
  3
• 氢受体数：
  10

制备方法与用途

生物活性

Dibutyryl-cGMP sodium (Bt2cGMP sodium) 是细胞可渗透的 cGMP 类似物，可优先激活 cGMP 依赖性蛋白激酶 (PKG)。Dibutyryl-cGMP sodium 抑制 γ 凝血酶刺激的人血小板中 [3H]-花生四烯酸的释放。Dibutyryl-cGMP sodium 可通过激活ATP 敏感的 K+ 通道而具有镇痛作用。

靶点

cGMP-dependent protein kinase (PKG);
ATP-sensitive K ⁺ channels

体外研究

Dibutyryl-cGMP is able to induce process elongation and branching in astrocytes resulting from a rapid, reversible and concentration-dependent redistribution of glial fibrillary acidic protein (GFAP) and actin filaments without significant change in protein levels.
When cells are co-incubated with Dibutyryl-cGMP (100 μM) stress fibre formation is prevented and cells acquired a stellate morphology in cerebellar astrocytes.
In cells treated with Dibutyryl-cGMP (100 μM, 2 h) the particulate fraction is nearly devoid of RhoA protein. Dibutyryl-cGMP prevents RhoA-membrane association.
Using the scratchwound model, the size of the wound is significantly smaller in cells treated with Dibutyryl-cGMP after the wound indicating that dbcGMP accelerates wound closure.

体内研究

Dibutyryl-cGMP (50-200 μg/paw; subcutaneous injection; male Wistar rats) treatment antagonizes the hyperalgesic effect of PGE2 in a dose-dependent manner. Maximal antinociceptive effect of DbcGMP is at 1 h after administration and last for plus 2 h.

Animal Model:	Male Wistar rats (180- 250 g) injection with Prostaglandin E2 (PGE2)
Dosage:	50 μg/paw, 75 μg/paw, 100 μg/paw and 200 μg/paw
Administration:	Subcutaneous injection
Result:	Antagonized the hyperalgesic effect of PGE2 (2 μg/paw), in a dose-dependent manner.